Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data

References

• BaldessariniRJ, VietaE, CalabreseJR, TohenM, BowdenCL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143–157. doi:10.3109/1067322100374795520415631
   PubMed Web of Science ®Google Scholar
• BlancoC, ComptonWM, SahaTD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions - III. J Psychiatr Res. 2017;84:310–317. doi:10.1016/j.jpsychires.2016.10.00327814503
   PubMed Web of Science ®Google Scholar
• TohenM, GreenfieldSF, WeissRD, ZarateCA, VaggeLM. The effect of comorbid substance use disorders on the course of bipolar disorder: a review. Harv Rev Psychiatry. 1998;6(3):133–141. doi:10.3109/1067322980900032110372281
   PubMed Web of Science ®Google Scholar
• TohenM, HennenJ, ZarateCM, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157(2):220–228. doi:10.1176/appi.ajp.157.2.22010671390
   PubMed Web of Science ®Google Scholar
• TreuerT, TohenM. Predicting the course and outcome of bipolar disorder: a review. Eur Psychiatry. 2010;25(6):328–333. doi:10.1016/j.eurpsy.2009.11.01220444581
   PubMed Web of Science ®Google Scholar
• TohenM, StrakowskiSM, ZarateC, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry. 2000;48(6):467–476. doi:10.1016/s0006-3223(00)00915-x11018220
   PubMed Web of Science ®Google Scholar
• VietaE, SalagreE, GrandeI, et al. Early intervention in bipolar disorder. Am J Psychiatry. 2018;175(5):411–426. doi:10.1176/appi.ajp.2017.1709097229361850
   PubMed Web of Science ®Google Scholar
• DionGL, TohenM, AnthonyWA, WaternauxCS. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry. 1988;39(6):652–657. doi:10.1176/ps.39.6.6523402925
   PubMedGoogle Scholar
• TohenM, WaternauxCM, TsuangMT. Outcome in mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990;47(12):1106–1111. doi:10.1001/archpsyc.1990.018102400260052244795
   PubMed Web of Science ®Google Scholar
• TohenM, WaternauxCM, TsuangMT, HuntAT. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord. 1990;19(2):79–86. doi:10.1016/0165-0327(90)90012-w2142702
   PubMed Web of Science ®Google Scholar
• TohenM, TsuangMT, GoodwinDC. Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. Am J Psychiatry. 1992;149(11):1580–1584. doi:10.1176/ajp.149.11.15801415828
   PubMed Web of Science ®Google Scholar
• TohenM, BowdenCL, CalabreseJR, et al. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry. 2006;189:515–519. doi:10.1192/bjp.bp.105.02032117139035
   PubMed Web of Science ®Google Scholar
• JuddLL, AkiskalHS, SchettlerPJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537. doi:10.1001/archpsyc.59.6.53012044195
   PubMed Web of Science ®Google Scholar
• O’DonovanC, AldaM. Depression preceding diagnosis of bipolar disorder. Front Psychiatry. 2020;11:500. doi:10.3389/fpsyt.2020.0050032595530
   PubMed Web of Science ®Google Scholar
• VietaE, BerkM, WangW, ColomF, TohenM, BaldessariniRJ. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord. 2009;119(1–3):22–27. doi:10.1016/j.jad.2009.02.02819324419
   PubMed Web of Science ®Google Scholar
• PacchiarottiI, BondDJ, BaldessariniRJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–1262. doi:10.1176/appi.ajp.2013.1302018524030475
   PubMed Web of Science ®Google Scholar
• KetterTA, HoustonJP, AdamsDH, et al. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry. 2006;67(1):95–101. doi:10.4088/jcp.v67n011316426094
   PubMed Web of Science ®Google Scholar
• TohenM, KatagiriH, FujikoshiS, KanbaS. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord. 2013;149(1–3):196–201. doi:10.1016/j.jad.2013.01.02223485111
   PubMed Web of Science ®Google Scholar
• TohenM, GoldAK, SylviaLG, et al. Bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [published correction appears in J Affect Disord. 2018 Jan 1;225:775–777]. J Affect Disord. 2017;217:183–189. doi:10.1016/j.jad.2017.03.07028411507
   PubMed Web of Science ®Google Scholar
• TohenM, ZarateCA, HennenJ, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099–2107. doi:10.1176/appi.ajp.160.12.209914638578
   PubMed Web of Science ®Google Scholar
• GitlinMJ, MintzJ, SokolskiK, HammenC, AltshulerLL. Subsyndromal depressive symptoms after symptomatic recovery from mania are associated with delayed functional recovery. J Clin Psychiatry. 2011;72(5):692–697. doi:10.4088/JCP.09m05291gre20673560
   PubMed Web of Science ®Google Scholar
• Zyprexa (olanzapine). Package Insert. Eli Lilly and Company; 2009.
   Google Scholar
• Sertoquel XR (quetiapine fuarate extended-release). Package Insert. AstraZenca Pharmaceutical LP; 2013.
   Google Scholar
• Latuda (lurasione HCL) tablets. Package Insert. Sunovion Pharmaceutical; 2017.
   Google Scholar
• VRAYLAR (cariprazine). Package Insert. Allergan plc; 2019.
   Google Scholar
• TohenM, VietaE, CalabreseJ, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published correction appears in Arch Gen Psychiatry. 2004 Feb;61(2):176]. Arch Gen Psychiatry. 2003;60(11):1079–1088. doi:10.1001/archpsyc.60.11.107914609883
   PubMed Web of Science ®Google Scholar
• TohenM, McDonnellDP, CaseM, et al. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. Br J Psychiatry. 2012;201(5):376–382. doi:10.1192/bjp.bp.112.10835722918966
   PubMed Web of Science ®Google Scholar
• LombardoI, SachsG, KolluriS, KremerC, YangR. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol. 2012;32(4):470–478. doi:10.1097/JCP.0b013e31825ccde522722504
   PubMed Web of Science ®Google Scholar
• ThaseME, BowdenCL, NashatM, et al. Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. Int J Psychiatry Clin Pract. 2012;16(2):121–131. doi:10.3109/13651501.2011.63268022296512
   PubMed Web of Science ®Google Scholar
• ChoDI, ZhengM, KimKM. Current perspectives on the selective regulation of dopamine D2 and D3 receptors. Arch Pharm Res. 2010;33(10):1521–1538. doi:10.1007/s12272-010-1005-821052931
   PubMed Web of Science ®Google Scholar
• TohenM. Cariprazine in bipolar disorders. J Clin Psychiatry. 2015;76(3):e368–e370. doi:10.4088/JCP.14com0960625830460
   PubMed Web of Science ®Google Scholar
• GirgisRR, SlifsteinM, D’SouzaD, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl). 2016;233(19–20):3503–3512. doi:10.1007/s00213-016-4382-y27525990
   PubMed Web of Science ®Google Scholar
• StoyanovD, AryutovaK, KandilarovaS, et al. Diagnostic task specific activations in functional MRI and aberrant connectivity of insula with middle frontal gyrus can inform the differential diagnosis of psychosis. Diagnostics (Basel). 2021;11(1):95. doi:10.3390/diagnostics1101009533435624
   PubMedGoogle Scholar
• DurgamS, EarleyW, LipschitzA, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173(3):271–281. doi:10.1176/appi.ajp.2015.1502016426541814
   PubMed Web of Science ®Google Scholar
• EarleyW, BurgessMV, RekedaL, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019;176(6):439–448. doi:10.1176/appi.ajp.2018.1807082430845817
   PubMed Web of Science ®Google Scholar
• EarleyWR, BurgessMV, KhanB, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord. 2020;22(4):372–384. doi:10.1111/bdi.1285231628698
   PubMed Web of Science ®Google Scholar
• HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. doi:10.1136/jnnp.23.1.5614399272
   PubMed Web of Science ®Google Scholar
• GuyW; National Institute of Mental Health (U.S.). Psychopharmacology research branch, early clinical drug evaluation program. In: Ecdeu Assessment Manual for Psychopharmacology. Rev. Rockville, Md.: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
   Google Scholar
• YoungRC, BiggsJT, ZieglerVE, MeyerDA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435. doi:10.1192/bjp.133.5.429728692
   PubMed Web of Science ®Google Scholar
• PosnerK, BrownGK, StanleyB, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. doi:10.1176/appi.ajp.2011.1011170422193671
   PubMed Web of Science ®Google Scholar
• MontgomerySA, ÅsbergM. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. doi:10.1192/bjp.134.4.382444788
   PubMed Web of Science ®Google Scholar
• YathamLN, VietaE, McIntyreRS, JainR, PatelM, EarleyW. Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications. Prim Care Companion CNS Disord. 2020;22(5):20m02611. doi:10.4088/PCC.20m02611
   Google Scholar
• PatelM, JainR, TohenM, MaleticV, EarleyWR, YathamLN. Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. Int Clin Psychopharmacol. 2021;36(2):76–83. doi:10.1097/YIC.000000000000034433230026
   PubMed Web of Science ®Google Scholar
• McIntyreRS, MasandPS, EarleyW, PatelM. Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J Affect Disord. 2019;257:600–606. doi:10.1016/j.jad.2019.07.02031344528
   PubMed Web of Science ®Google Scholar
• KapczinskiNS, NarvaezJC, MagalhãesPV, et al. Cognition and functioning in bipolar depression [published correction appears in Rev Bras Psiquiatr. 2016 Jul–Sep;38(3):266]. Braz J Psychiatry. 2016;38(3):201–206. doi:10.1590/1516-4446-2014-155826870909
   PubMed Web of Science ®Google Scholar
• BonnínCM, Martínez-AránA, TorrentC, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord. 2010;121(1–2):156–160. doi:10.1016/j.jad.2009.05.01419505727
   PubMed Web of Science ®Google Scholar
• RosaAR, Sánchez-MorenoJ, Martínez-AranA, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5. doi:10.1186/1745-0179-3-517555558
   PubMedGoogle Scholar
• ZarateCA, TohenM, LandM, CavanaghS. Functional impairment and cognition in bipolar disorder. Psychiatr Q. 2000;71(4):309–329. doi:10.1023/a:100463220668411025910
   PubMed Web of Science ®Google Scholar
• PatelMD, VietaE, CalabreseJ, WhelanJ, TohenM. Efficacy of cariprazine on functioning in patients with bipolar depression: post hoc analysis of a randomized, placebo-controlled trial. Poster to be presented at: American Psychiatric Association Annual Meeting; 5 2021; virtual.
   Google Scholar
• VietaE, CalabreseJR, WhelanJ, TohenM, EarleyW. The efficacy of cariprazine on function in patients with bipolar depression: a post hoc analysis of a randomized controlled trial. Curr Med Res Opin. 2021.
   Web of Science ®Google Scholar
• KetterTA, SachsGS, DurgamS, et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label study. J Affect Disord. 2018;225:350–356. doi:10.1016/j.jad.2017.08.04028843918
   PubMed Web of Science ®Google Scholar
• EarleyWR, BurgessM, RekedaL, et al. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020;263:386–395. doi:10.1016/j.jad.2019.11.09831969269
   PubMed Web of Science ®Google Scholar
• CalabreseJR, Keck, JrPE, StaraceA, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76(3):284–292. doi:10.4088/JCP.14m0908125562205
   PubMed Web of Science ®Google Scholar
• SzatmáriB, BarabássyÁ, HarsányiJ, et al. Cariprazine safety in adolescents and the elderly: analyses of clinical study data. Front Psychiatry. 2020;11:61. doi:10.3389/fpsyt.2020.0006132194443
   PubMed Web of Science ®Google Scholar
• RiccobeneT, RiesenbergR, YeungP, EarleyW, HankinsonA, PericlouA. Pharmacokinetics and safety/tolerability profile of cariprazine in pediatric patients with schizophrenia or bipolar I disorder. Presented at: 67th American Academy of Child and Adolescent Psychiatry Annual Meeting; 1019–24, 2020; virtual.
   Google Scholar